![catheter-operating-room](/sites/default/files/2018-08/catheter-operating-room.jpg)
The Food and Drug Administration authorized administering the monoclonal antibodies bamlanivimab and etesevimab together to treat patients 12 and older with mild-to-moderate COVID-19 who are at high risk for progressing to severe disease but not hospitalized or on oxygen therapy.